Medicenna To Present 4 Year Follow-Up Phase 2b Bizaxofusp Survival Data In Recurrent Glioblastoma At The Society For Neuro-Oncology 2023 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Medicenna Therapeutics Corp. (TSX:MDNA, OTC:MDNAF) will present long-term follow-up data from the Phase 2b clinical trial of bizaxofusp (formerly known as MDNA55) at the Society for Neuro-Oncology 2023 Annual Meeting. The data shows that bizaxofusp more than doubled the median survival in end-stage recurrent glioblastoma patients. The company is actively pursuing potential partnerships to conduct the Phase 3 LIGHT trial and commercialize bizaxofusp in key global markets.
November 09, 2023 | 2:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Medicenna's presentation of positive Phase 2b bizaxofusp data could boost investor confidence and potentially attract partnership opportunities for Phase 3 trials and commercialization.
The positive Phase 2b data for bizaxofusp indicates the drug's potential effectiveness, which could attract investors and potential partners for further development and commercialization. This could positively impact Medicenna's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
The positive Phase 2b data for bizaxofusp and the company's pursuit of partnerships for further trials and commercialization could positively impact Medicenna's OTC-listed stock.
The positive Phase 2b data for bizaxofusp indicates the drug's potential effectiveness, which could attract investors and potential partners for further development and commercialization. This could positively impact Medicenna's OTC-listed stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100